MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis https://t.co/HusL5Uftit
71 followers
906 followers
New article: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis https://t.co/wT3jrQGACc #livercancer #oncology https://t.co/ZZznLI721M
906 followers
New article: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis https://t.co/FffUIrX1kp #pancreaticcancer #oncology https://t.co/1BHZB7eXiR